



Description générale

Daunorubicin is an anthracycline antineoplastic agent that inhibits DNA and RNA synthesis. It is used in treatment protocols for acute lymphoblastic leukaemia, acute myelogenous leukaemia and acute promyelocytic leukaemia.

| | |
|----------------------------|--|
| INN | Daunorubicin |
| Codes ATC | L01DB02 |
| Type de médicament | Chemical agent |
| Historique des statuts LME | Ajouté pour la première fois en 1999 (TRS 895) pour Lymphoid leukaemia, not elsewhere classified Ajouté en 1999 (TRS 895) pour Acute myeloid leukaemia with recurrent genetic abnormalities Ajouté en 1999 (TRS 895) pour Myeloid leukaemia |
| Wikipédia | Daunorubicin  |
| DrugBank | Daunorubicin  |

Recommandations

Section Cytotoxic medicines

Parenteral > General injections > IV: 50 mg in vial (as hydrochloride) powder for injection; 20 mg in vial (as hydrochloride) powder for injection; 2 mg per mL in vial (as hydrochloride); 5 mg per mL in vial (as hydrochloride)

Indications

Lymphoid leukaemia, not elsewhere classified

Myeloid leukaemia

Acute myeloid leukaemia with recurrent genetic abnormalities

